In The Pipeline

Like any other scientific endeavor, clinical testing of novel drug compounds is a complex, time-consuming, resource-intensive process with no guaranteed results. But, as described here, Bristol-Myers Squibb is committed to pursuing such clinical development and, in doing so, to bringing new hope to patients.

Please click on product name to see the Full U.S. Prescribing Information for OPDIVO^?, YERVOY^?, POMALYST^?, EMPLICITI^?, IDHIFA^?, ISTODAX^?, ORENCIA^?, NULOJIX^?, ELIQUIS^?, REVLIMID^?, REBLOZYL^?,?including Boxed WARNINGS for ELIQUIS^?, REVLIMID^?, POMALYST^?? and Boxed WARNING for YERVOY^? regarding immune-mediated adverse reactions and IDHIFA^? regarding differentiation syndrome?and INREBIC^? regarding encephalopathy including Wernicke's.

? Development Partnership: OPDIVO, YERVOY, Relatlimab, EP4: Ono (our collaboration with Ono also includes other early stage compounds); EMPLICITI: AbbVie; Bempegaldesleukin: Nektar; Cabiralizumab: Five Prime; Cabozantinib: Exelixis; ELIQUIS: Pfizer; Factor XIa Inhibitor: Janssen; HSP47: Nitto Denko; GEMoaB CD3xPSCA, GEM333: GeMoaB Monoclonals GmbH; bb21217, ide-cel: bluebird bio; REBLOZYL: Acceleron Pharma, IDHIFA: Agios Pharmaceuticals

^ Trial(s) exploring various combinations
# Partner-run study
? Product is marketed as IMNOVID^? in the EU
+ Idecabtagene vicleucel
○ Orvacabtagene autoleucel, being developed by Juno Therapeutics Inc.,?A Bristol-Myers Squibb Company
* Lisocabtagene maraleucel
NSCLC = Non-Small Cell Lung Cancer
SCLC = Small Cell Lung Cancer
SCCHN = Squamous Cell Carcinoma of the Head & Neck
HMA = Hypomethylating Agent
TCE = T-Cell Engager
ADC = Antibody Drug Conjugate
ESA = Erythoropoiesis-Stimulating Agent

For information on approved uses, refer to approved product labeling.Phase I - clinical trials investigating safety of an investigational medicine in a small number of human subjects.Phase II - clinical trials investigating dosing, safety and efficacy of an investigational medicine in a small number of patients who have the disease or condition under study.Phase III - clinical trials investigating the safety and efficacy of an investigational medicine in a larger number of patients who have the disease or condition under study. For purposes of this chart, this includes the regulatory approval process prior to receiving marketing approval in the first major market.